Relfydess Is Coming: What Aesthetic Providers Should Do Now

April 21, 2026

Relfydess (relabotulinumtoxinA) has quickly become one of the most talked-about “next-generation” neurotoxins in aesthetic medicine. As a ready-to-use, complex-free liquid botulinum toxin type A, it is positioned to address the growing patient demand for longer-lasting results and the industry shift toward standardized formulations.

With Phase 3 data indicating rapid onset and sustained improvement for glabellar lines and crow’s feet, understanding its clinical profile and practice management implications is essential for aesthetic providers preparing for its integration.

What you will learn in this article:

The unique clinical characteristics of Relfydess, including its ready-to-use liquid formulation and complex-free profile.
Key insights from Phase 3 trials regarding onset time and duration of effect for glabellar and lateral canthal lines.
Practical considerations for integrating a longer-duration neurotoxin into your practice’s scheduling and revenue models.
Actionable steps to prepare your team, update patient consents, and refine your neuromodulator portfolio messaging.

Why Everyone’s Talking About Relfydess

Relfydess (relabotulinumtoxinA) is a ready‑to‑use, complex‑free liquid botulinum toxin type A with Phase 3 data showing rapid onset and sustained improvement for glabellar lines and crow’s feet in many patients, as seen in an Aesthetic Surgery Journal Phase 3 glabellar trial, the READY‑2 lateral canthal lines study, and ASDS 2024 coverage of long‑term safety.

It’s also positioned at the intersection of two powerful trends:

Patients wanting fewer visits and longer‑lasting results.
Manufacturers moving toward ready‑to‑use, more standardized toxin formulations.

At the same time, press releases and conference coverage—such as Galderma’s IMCAS 2025 RELAX Phase IIIb update and ASDS 2024 READY‑4 data release—emphasize “Day‑1 onset” and “6‑month results,” which can easily create unrealistic expectations if they’re repeated without context.

Relfydess in 60 Seconds: What Makes It Different?

At a high level, Relfydess differs from legacy neuromodulators in three main ways:

It’s supplied as a ready‑to‑use liquid at 10 units per 0.1 mL (100 units/mL), with no reconstitution step, as described in the UK Summary of Product Characteristics (SmPC).
It’s a complex‑free botulinum toxin type A1 formulation, placing it in the same conceptual category as other complex‑free BoNT‑A products reviewed in publications such as “Complexing Protein‑Free Botulinum Neurotoxin A Formulations”.
Phase 3 data support rapid onset and durable effect for many patients, with onset as early as Day 1 in a subset and sustained responses out toward six months in a significant proportion of subjects.

That combination—no mixing, strong durability data, and a complex‑free formulation—is exactly why there is so much buzz around Relfydess among injectors and industry watchers.

What Providers Should (and Shouldn’t) Expect

When you strip away the marketing language, a few practical realities emerge:

Onset is still a range, not a promise. In READY‑2, the median patient‑reported time to onset was two days, with about one‑third of patients reporting onset within one day, not every patient seeing results immediately (as reported in the full READY‑2 publication and its journal abstract). Framing it as “many patients notice improvement within a few days” keeps expectations grounded.
Onset is still a range, not a promise. In READY‑2, the median patient‑reported time to onset was two days, with about one‑third of patients reporting onset within one day, not every patient seeing results immediately. Framing it as “many patients notice improvement within a few days” keeps expectations grounded.
Duration is better thought of as a curve. Phase 3 and Phase IIIb results show a meaningful proportion of patients maintaining improvement around six months, but not everyone will last that long.
Units are not interchangeable. Relfydess units are specific to this formulation. The SmPC explicitly notes that its potency units cannot be compared to or converted into units of other botulinum toxin type A products.
Single‑use vials change workflow. Patient leaflets and product information make clear that each vial is intended for a single patient in a single treatment session, with any remaining solution discarded (as stated in the Swedish SmPC and the UK patient information leaflet). Practices will need to adjust if they are accustomed to stretching reconstituted vials.

How Relfydess Could Change Your Practice Rhythm

Even before you touch a vial, it’s worth thinking about how a longer‑duration, ready‑to‑use neurotoxin might impact your systems:

Visit cadence: Some patients will move from four toxin visits per year to two or three. That can be a win for time‑poor patients—but it also reduces built‑in opportunities for add‑on services if you don’t adjust.
Scheduling and memberships: Any membership or recall system that quietly assumes “every three months” will need to be recalibrated when you have a mix of 3–4‑month and 5–6‑month toxins in the same panel.
Revenue mix: Longer gaps between toxin appointments might mean fewer short visits but more time per visit for higher‑value combined treatments, if you intentionally design for that.

3 Things to Do Now—While Preparing for Relfydess

Note: Relfydess is not yet FDA-approved for use in the United States. The steps below are intended to help practices prepare proactively for its arrival and approval, so you are ready to integrate it efficiently once it becomes available.

1. Clean Up Your Neurotoxin Portfolio Messaging

If you’re already offering more than one neuromodulator, you likely have some “fuzzy edges” in how your team describes differences in onset, duration, spread, and price.

Before Relfydess becomes available in your market, tighten that up:

Create one internal, one‑page comparison that’s strictly clinician‑facing.
Give your front desk and coordinators a short script that explains differences without overselling any single brand.
Make sure no one is promising instant results or guaranteed six‑month duration, regardless of what patients have read in consumer pieces like Derm Digest’s coverage of the EU launch or early consumer‑facing explainers (if you choose to cite any).

2. Update Consents and Policies for Longer Duration

Any time you plan to add a product that may last longer, it’s worth getting your consent language and policies ready in advance.

Make sure consents describe onset and duration as ranges, not guarantees, aligned with trial data rather than marketing slogans.
Decide in advance how you’ll handle perceived early wear‑off or dissatisfaction with a long‑lasting result.
Align your team so everyone gives the same answers when patients ask, “What if I don’t like it?”

3. Start Thinking About Who Your First 20 Relfydess Patients Will Be

When approval comes, your first cycles with any new toxin should be treated as a structured learning phase, not a free‑for‑all. Identifying likely candidates now means you’ll be ready to move quickly.

Identify ideal early adopters: time‑poor, realistic, loyal patients who understand you’re refining protocols.
Plan follow‑ups at 1–2 weeks, 3–4 months, and around six months for those patients so you can build your own practice‑specific onset and duration curves, rather than relying only on pooled trial averages.

Key Takeaways

Relfydess offers a ready-to-use, complex-free formulation that simplifies preparation by eliminating the reconstitution step.
Clinical trials demonstrate rapid onset for many patients, but providers should manage expectations by framing onset and duration as a range rather than a guarantee.
The product’s single-use vial requirement and unique potency units necessitate specific adjustments in dosing protocols and inventory management.
Integrating a longer-duration toxin will require strategic updates to practice scheduling, membership models, and patient consent forms.
A structured rollout targeting ideal early adopters will help practices establish reliable, real-world data on product performance.

Where to Go Deeper: Clinical Evidence, Dosing, and Practice Modeling

This blog is intentionally high‑level and time‑sensitive. If you want a deeper dive into trial data, onset and duration distributions, unit non‑interchangeability, storage and handling, and the practice‑management math behind longer‑duration toxins, you’ll find that in the full evergreen guide:

Read the full provider guide to Relfydess (relabotulinumtoxinA)

Staying Ahead of the Curve on Neurotoxins

Relfydess is part of a broader shift: more neurotoxin brands, more “long‑lasting” positioning, and more ready‑to‑use liquids entering the space. The practices that adapt best won’t be the ones chasing every new label—they’ll be the ones with strong fundamentals who can evaluate new products calmly, plug them into existing systems, and explain their decisions clearly to patients.

If you want to shore up those fundamentals—anatomy, dosing, complication management, and communication—so you’re ready for Relfydess and whatever comes next, consider formal training and certification.

The IAPAM’s hands‑on programs in Botox and neuromodulator injections, along with its certification pathways, are designed to help you stay current across all injectables, not just the newest one in the headlines. You can learn more about live training options here:

IAPAM Botox and injectable training

FAQs

What is the main difference between Relfydess and traditional neuromodulators?
Relfydess is a ready-to-use, complex-free liquid formulation of botulinum toxin type A. It does not require reconstitution and comes at a fixed concentration of 10 units per 0.1 mL, simplifying preparation.

How quickly does Relfydess take effect?
While some patients report onset as early as Day 1, the median patient-reported time to onset in the READY-2 trial was two days. Providers should counsel patients that onset times can vary.

Can I use the same unit dosing for Relfydess as I do for Botox or Dysport?
No. Relfydess units are specific to its formulation and are not interchangeable with units of other botulinum toxin type A products. Providers must follow product-specific dosing guidelines.

How long do the results of Relfydess last?
Phase 3 data indicate that a meaningful proportion of patients maintain clinical improvement around six months. However, duration is a curve, and individual patient results will vary.

How should I adjust my practice scheduling for a longer-duration toxin?
Practices may see patients shift from four visits per year to two or three. It is important to recalibrate membership models, update consent forms to reflect duration ranges, and intentionally design longer visits to include adjunct services.

Thinking About Offering Botox®? Start Here First

Before you inject, understand how Botox® works, how it differs from Dysport®, and what experienced physicians do to avoid complications and improve patient outcomes.

Thinking About Botox®? Read This First

Botox® vs. Dysport®, key technique insights, and 9 expert recommendations to help you avoid common mistakes as a new cosmetic injector.

References:

Aesthetic Surgery Journal – Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines – November 15, 2024
Dermatologic Surgery – Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study – March 1, 2025 (Epub December 18, 2024)
Galderma – IMCAS 2025: New Galderma phase IIIb data reinforce rapid onset and long-lasting aesthetic improvement with RelabotulinumtoxinA (Relfydess) – January 31, 2025
Galderma – ASDS 2024: New phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess) – October 21, 2024
Derm Digest – ASDS 2024: Galderma’s Liquid Toxin Shows Long-term Safety for Frown Lines, Crow’s Feet – October 20, 2024
Derm Digest – Buoyed by New Data, Galderma’s Liquid Toxin Launches Across Europe – February 3, 2025
Medicines.org.uk – Relfydess 100 units/mL solution for injection – Summary of Product Characteristics – January 1, 2026 (accessed 2026)
Swedish Medical Products Agency – Relfydess 100 units/mL, solution for injection – Patient Information Leaflet – 2024 (accessed 2026)
PMC (Open Access Review) – Complexing Protein-Free Botulinum Neurotoxin A Formulations: A Review – 2024
ScienceDirect – Treatment of Lateral Canthal Lines With RelabotulinumtoxinA: Clinical Efficacy and Safety Results From the READY-2 Phase 3 Trial – 2024 (online ahead of print)

Celebrating 20 Years of Training in Botox®, Aesthetic Medicine
and Medical Weight Management

Celebrating 20 Years of Excellence in Botox®, Aesthetic Medicine & Medical Weight Management Training & Certification